Intra-arterial chemotherapy for brain tumors
Ben H. Brouhard, MD
Samuel J. Hassenbusch, MD, PhDAddress reprint requests to S.J.H., Department of Neurosurgery, S80-803, The Cleveland Clinic Foundation, One Clinic Center, 9500 Euclid Avenue, Cleveland, Ohio 44195-5226.
James H. Anderson, PhD
Donald M. Whiting, MD
Direct comparisons of theoretical modeling with actual drug delivery can lead to improved brain tumor therapy. In this study, normal and brain tumor-bearing rabbits received infusions of BCNU, or carmustine (1,3-bis [2-chlorethyl]-l-nitrosourea), with ethanol or hyperoxygenated perfluorocarbons as BCNU diluent. When ethanol was used as a diluent, right (infused) hemisphere left (noninfused) hemisphere ratios of BCNU concentrations in both rabbit groups were markedly lower than had been predicted with theoretical pharmacokinetic modeling. When perfluorocarbons were used as a diluent, ratios of BCNU were significantly improved. These laboratory studies were directly translated into a two-phase protocol for human brain tumor patients. This combined research program demonstrates the successful integration of laboratory and clinical programs.